Results 241 to 250 of about 80,161 (286)
Some of the next articles are maybe not open access.
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Cell Metabolism, 2021 Sodium glucose co-transporter (SGLT) 2 inhibitors reduce the risk of kidney failure in patients with and without type 2 diabetes (T2D). Although the precise underlying mechanisms for these nephroprotective effects are incompletely understood, various ...
Hiddo Lambers Heerspink, Taha Sen
exaly +2 more sources
International Journal of Molecular Sciences, 2021 Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes.
William Durante +2 more
exaly +2 more sources
Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis
Journal of Cellular Physiology, 2022AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi +5 more
openaire +2 more sources
British Journal of Anaesthesia, 2019 BACKGROUND Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated with sodium-glucose co-transporter-2 inhibitors (SGLT2i).
Roelof Van Wijk, Emily Meyer
exaly +2 more sources
Sodium–glucose co-transporter-2 inhibitors
2022Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee +2 more
openaire +1 more source
European Heart Journal, 2023
BACKGROUND AND AIMS To investigate the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore ...
M. Banerjee +3 more
semanticscholar +1 more source
BACKGROUND AND AIMS To investigate the cardiovascular effects of sodium-glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore ...
M. Banerjee +3 more
semanticscholar +1 more source
Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney
Journal of Diabetes and its Complications, 2016Diabetic ketoacidosis is a serious metabolic condition that may occur in patients with either Type 1 or Type 2 diabetes. The accumulation of ketoacids in the serum is a consequence of insulin deficiency and glucagon excess. Sodium Glucose Transporter 2 (SGLT2) inhibitors are novel therapeutic treatments for improving glucose homeostasis in patients ...
Biff F, Palmer +3 more
openaire +2 more sources